How to Buy Rani Therapeutics Holdings Stock
Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics.
Rani Therapeutics Holdings stock last closed at $6.56, down 6.15% from the previous day, and has increased 42.92% in one year. It has overperformed other stocks in the Biotechnology industry by 0.67 percentage points. Rani Therapeutics Holdings stock is currently +260.44% from its 52-week low of $1.82, and -25.03% from its 52-week high of $8.75.
As of Apr 25, 2024, there are 50.16M shares of RANI outstanding. The market cap of RANI is $329.03M. In the last 24 hours, 187,816 RANI shares were traded.
How to Buy Rani Therapeutics Holdings Stock
Not sure how to invest in Rani Therapeutics Holdings stock? Here's how.
- Figure out where to buy Rani Therapeutics Holdings stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Rani Therapeutics Holdings stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Select your method of payment and add your information.
- Evaluate Rani Therapeutics Holdings stock: The Rani Therapeutics Holdings ticker symbol is RANI. Is Rani Therapeutics Holdings stock a good investment? Should you buy shares of RANI? How do RANI's underlying business fundamentals look? Do top analysts think Rani Therapeutics Holdings is a good buy? Why has RANI's stock price moved recently? (Hint: Our stock analysis website can help you decide if RANI is a good stock to buy).
- Execute your RANI trade: Decide if you will purchase RANI shares at the current market price or use a limit order to purchase RANI shares at a specific price.
- Get notifications regarding your RANI investment: Create a watchlist to watch your new investment in Rani Therapeutics Holdings stock.
Step 1: Figure out where to buy Rani Therapeutics Holdings stock
You need an online brokerage account to access the NASDAQ market and buy RANI stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global financial markets: From Technology to Real Estate, New York to Tokyo — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal info so you can buy RANI stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start a new trading account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have finished signing up on the best stock trading app for beginners, you need to deposit funds:
Check out this video walkthrough for more details transferring funds into your new investment account.
Step 4: Evaluate Rani Therapeutics Holdings stock
After you have chosen the best place to buy Rani Therapeutics Holdings stock, it's critical to analyze their stock prior to buying, so you can wrap your head around the risk and upside.
Rani Therapeutics Holdings quick stats
Rani Therapeutics Holdings Fundamentals
WallStreetZen was created to help average investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on RANI's stock page.
Is RANI stock undervalued or overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge RANI's fair value.
Using relative valuations ratios:
- RANI may be overvalued based on its P/B ratio of 25.57x, relative to Biotechnology industry P/B ratio of 5.8x
You can do more valuation research on RANI's stock here.
A look at RANI Cashflows and Balance Sheet
Signs that RANI is financially healthy:
- There are more short-term assets than short-term liabilities on the RANI balance sheet.
- There are more short-term assets than long-term liabilities on the RANI balance sheet.
Signs that RANI is not financially healthy:
- RANI has cash burn of 52465000. It does not have sufficient cash and short-term investments to cover this.
- RANI has $48.54M in cash and short term investments. This is not enough to cover its annual cash burn of $52.47M.
- RANI has a relatively high debt to equity ratio of 2.52.
Is Rani Therapeutics Holdings stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 3 Wall Street analysts who research RANI, the consensus analyst rating on Rani Therapeutics Holdings is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Rani Therapeutics Holdings stock forecast page.
RANI Momentum
RANI Growth Numbers
Last year, RANI revenue was $0.00. In the past four year, RANI's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 28.62%.
Learn more about RANI's earnings and revenue performance here.
Who is buying/selling RANI?
Over the past 12 months, insiders at RANI have bought more shares than they have sold.
Talat Imran, Chief Executive Officer of RANI, was the latest RANI insider to buy. They bought $22,700.00 worth of RANI shares on Dec 6, 2023.
Research more about who owns RANI shares here.
Does RANI provide a stable income stream?
No, Rani Therapeutics Holdings doesn't provide an income stream by paying out dividends.
RANI Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your RANI trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific dollar amount, place a limit order.
Hit the Open Trade button and your broker will place the order.
If you want more assistance investing in stocks on eToro, click the helpful video below:
Step 6: Get notifications regarding your RANI investment
Now that you own some RANI stock, you'll want to stay up-to-date on your new investment.
Add RANI to a watchlist to get alerted to the latest events about your RANI stock.
RANI Feed
How to Buy Stock in Rani Therapeutics Holdings
To reiterate, here are the 6 steps for buying Rani Therapeutics Holdings stock:
- Figure out where to buy Rani Therapeutics Holdings stock
- Create a brokerage account
- Deposit funds into your investment account
- Evaluate Rani Therapeutics Holdings stock
- Execute your RANI trade
- Get notifications regarding your RANI investment
If you are looking for a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Rani Therapeutics Holdings, hit the button below to create your watchlist.
More Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.